









FORM PTO-1449				ATTY DOCKET NO.		SERIAL NO.	
INFORMATION DISCLOSURE STATEMENT				20784/4		09/745,776	
				APPLICANT(S): Demuth et al.			
				FILING DATE: 12/22/2000		ART UNIT: 1614	
UNITED STATES PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FIL. DATE IF APPR
<u>D</u>	AA	2,961,377	11-1960	Shapiro et al.	167	65	
	AB	3,960,949	6-1976	Ahrens et al.	260	564 B	
	AC	4,935,493	6-1990	Bachovchin et al.	530	331	
	AD	5,433,955	7-1995	Bredehorst et al.	424	94.3	
	AE	5,512,549	4-1996	Chen et al.	514	12	
	AF	5,614,379	3-1997	MacKellar	435	68.1	
	AG	5,624,894	4-1997	Bodor	514	2	
<u>D</u>	AH	6,006,753	12-1999	Efendic	128	898	8/21/97
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN YES/NO
<u>D</u>	BD	WO 00/53171	9-14-00	PCT	A61K	31/155	Y
* No Translation	BE	DT 25 42598 A1	10-11-74	DE	C07C	129/16	N
* No Translation	BF	FR 2696740	10-13-92	FR	C07D	207/404	N
* No Translation	BG	FR 2085665	3-3-71	FR	A61K	27/00	N
<u>D</u>	BH	WO 93/08259 A2	4/29/93	PCT	C12N		Y
	BI	WO 95/11689	5/4/95	PCT	A61K	37/00	Y
	BJ	EP 0 708 179 A2	10/13/95	EPO	C12N	15/16	Y
	BK	0 658 568 A1	12/2/94	EPO	C07K	14/605	Y
	BL	WO 97/45117	12/4/97	PCT	A61K	31/435	Y
	BM	WO 97/40832	11/6/97	PCT	A61K	31/425	Abstract only
<u>D</u>	BN	WO 95/15309	6/8/95	PCT	C07D	207/16	Y
* No Translation	BO	DD 0 296 075	11/21/91	DD			N
<u>D</u>	BP	JP 4334357 A2	11/20/92	JP	C07C	233/57	Abstract only

* Considered 24 February 2003

FORM PTO-1449		ATTY DOCKET NO.	SERIAL NO.
INFORMATION DISCLOSURE STATEMENT		20784/4	09/745,776
		APPLICANT(S): Demuth et al.	
		FILING DATE: 12/22/2000	ART UNIT: 1614
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)			
	CC	Campbell, I.W., Sulphonylureas and metformin: efficacy and inadequacy. 3:33-51 (1990).	
	CD	Mercla Index, 11 th Edition, Page 934	
	CE	Martindale the Extra, Pharmacopoeia, Page 1619	
	CG	J. Lin et al.: "Inhibition of depeptidyl peptidase IV by fluoroolefin-containing n-peptidyl-0-hydroxylamine peptidomimetics" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, Vol. 95, November 1998 (1998-11)	
	CH	KOROM, S. et al., Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients, Transplantation Vol. 63, pg 1495-1500, Nov. 10, 1997	
	CI	TANAKA, S. et al., Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV. Int. J. Immunopharmacol. Vol. 19, No. 1, Pg 15-24 (1997)	
	CJ	WETZL, W. et al., Effects of the CLIP fragment ACTH 20-24 on the duration of REM sleep episodes. Neuropeptides, 31, (1), Pg 41-45 (1997)	
	CK	THORENS, B et al., Glucagon-Like Peptide-I and the Control of Insulin Secretion in the Normal State and in NIDDM. Diabetes 42:1219-1225 (1993)	
	CL	ORSKOV C. et al., Proglucagon Products in Plasma of Noninsulin-dependent Diabetics and Nondiabetic Controls in the Fasting State and After Oral Glucose and Intravenous Argine. J. Clin. Invest. 87:415-423 (1991)	
	CM	PAULY, R. et al., Improved Glucagon Tolerance in Rats Treated with the Dipeptidyl Peptidase IV (CD26) Inhibitor ILE-Thaxolidide. Metabolism 48:385-389 (1999)	
	CN	GUTNIAK, M. K. et al., Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM. Diabetes Care 17:1039-1044, (Sept. 1994)	
	CO	CHEMICAL ABSTRACTS, vol. 115. No. 15, 14. Oktober 1991 (1991-10-14) Columbus, Ohio, US; abstract no. 149947q, SCHOEN EKKEHARD ET AL: "Dipeptidyl peptidase IV in the immune system.Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes" Seite 37; XP002114197 Zusammenfassung & BIOL. CHEM. HOPPE-SEYLER, Bd. 372, Nr. 5, 1991, Seiten 305-311,	
	CP	CHEMICAL ABSTRACTS, vol. 126, no. 2, 13. Januar 1997 (1997-01-13) Columbus, Ohio, US; abstract no. 16161j, STOECKEL A. ET AL: "Competitive inhibition of proline specific enzymes by amino acid thioxopyrrolidides and thiazolidides" Seite 241; XP002114198 Zusammenfassung & PEPT: CHEM., STRUCT.BIOL., PROC.AM.PEPT.SYMP., Nr. 14, 1995, Seiten 709-710,	
	CQ	CHEMICAL ABSTRACTS, vol. 118, no. 25, 21. Juni 1993 (1993-06-21) Columbus, Ohio, US; abstract no. 255342k, Seite 933; XP002114199 Zusammenfassung & JP 04 334357 A (FUJEREBIO INC) 20. November 1992 (1992-11-20)	
	CR	ARAI, H. ET AL: "Synthesis of prolyl endopeptidase inhibitors and evaluation of their structure-activity relationships : in vitro inhibition of prolyl endopeptidase" CHEMICAL AND PHARMACEUTICAL BULLETIN., Bd. 41, Nr. 9, 1993	

21. February 2003

FORM PTO-1449		ATTY DOCKET NO.	SERIAL NO.
INFORMATION DISCLOSURE STATEMENT		20784/4	09/745,776
		APPLICANT(S): Demuth et al.	
		FILING DATE: 12/22/2000	ART UNIT: 1614
	CS	WINSLOW, R., Novartis Drug Alters Picture for Diabetes. <i>Wall Street Journal</i> , Wed. Dec. 27, 2000, p. B2.	
	CT	WILLMS, B. et al., Gastric Emptying, Glucose Response, and Insulin Secretion after a Liquid Test Meal: Effects of Exogenous Glucagon-Like Peptide-1 (GLP-1)-(7-36) Amide in Type 2 (Noninsulin-Dependent) Diabetic Patients. <i>JCEM</i> 81:327332 (1996) No. 1 327-332	
	CU	HENDRICK, G.K. et al., Glucagon-Like Peptide-I-(7-37) Suppresses Hyperglycemia in Rats. <i>Metabolism</i> Vol. 42, No. 1, pg 1-6 (Jan. 1993)	
	CV	DEACON, C. et al., Degradation of Glucagon-Like Peptide-1 by Human Plasma in Vitro an N-Terminally Truncated Peptide that is a Major Endogenous Metabolite in Vivo. <i>JCEM</i> 80:952-957, (April 25, 1995)	
	CW	HOFFMAN, T. et al., Inhibition of Dipeptidyl Peptidase IV (DPIV) by anti-DP IV antibodies and non-substrate X-X-Pro- Oligopeptides Ascertained by Capillary Electrophoresis. <i>Journal of Chromatography A</i> , 716 355-362 (1995)	
	CX	NAUCK, M.A. et al., Normalization of Fasting Hyperglycaemia by Exogenous Glucagon-Like Peptide I (7-36 Amide) in Type 2 (Non-insulin-dependent) Diabetic Patients. <i>Diabetologia</i> 36:741-744 (1993)	
Examiner: 		Date: 21 February 2003	